Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

scientific article

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1200/JCO.2011.39.4767
P932PMC publication ID3383121
P698PubMed publication ID22454414

P50authorEric J SmallQ97531370
Michael A. CarducciQ114718060
Michael J. MorrisQ38329744
Philip W. KantoffQ42532150
Susan HalabiQ42896002
P2093author name stringDaniel George
Nicholas J Vogelzang
Walter M Stadler
J Paul Monk
William Kevin Kelly
John F Mahoney
Ellen Kaplan
P2860cites workDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 studyQ46817220
Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancerQ53308080
Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancerQ60156367
Measurement of plasma levels of vascular endothelial growth factor in prostate cancer patients: relationship with clinical stage, Gleason score, prostate volume, and serum prostate-specific antigenQ79314357
Clinical Outcomes in Elderly Patients with Metastatic Colorectal Cancer Receiving Bevacizumab and Chemotherapy: Results from the BRiTE Observational Cohort StudyQ84792458
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerQ27860681
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerQ29614302
Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancerQ33561160
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.Q33767866
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206Q33813718
Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancerQ34281216
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.Q34441553
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guidelineQ34523108
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialQ34586436
Tumor angiogenesis correlates with metastasis in invasive prostate carcinomaQ35833169
Vascular endothelial growth factor (VEGF) expression in human prostate cancer: in situ and in vitro expression of VEGF by human prostate cancer cellsQ38474642
Expression of vascular endothelial growth factor receptors in human prostate cancerQ42477154
Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B studyQ43566256
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.Q44381567
The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.Q46365760
P433issue13
P407language of work or nameEnglishQ1860
P921main subjectprostate cancerQ181257
bevacizumabQ413299
docetaxelQ420436
placeboQ269829
phase III clinical trialQ42824827
P304page(s)1534-1540
P577publication date2012-03-26
P1433published inJournal of Clinical OncologyQ400292
P1476titleRandomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401
P478volume30

Reverse relations

cites work (P2860)
Q39863679A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy
Q47564776A Simple Method for Deriving the Confidence Regions for the Penalized Cox's Model via the Minimand Perturbation
Q95261850A case of castration-resistant prostate cancer with liver metastases achieved a complete response by docetaxel chemotherapy
Q36934749A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases
Q92379255A multicenter observational study of the real-world use of docetaxel for metastatic castration-resistant prostate cancer in China
Q33439003A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study
Q35018896A multicenter, randomized clinical trial comparing the three-weekly docetaxel regimen plus prednisone versus mitoxantone plus prednisone for Chinese patients with metastatic castration refractory prostate cancer
Q40120703A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.
Q40182500A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer
Q34657338A phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer
Q36984477A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma
Q54364572A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.
Q33415009A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients
Q46867730A randomized, double-blind, placebo-controlled, Phase II study with and without enzastaurin in combination with docetaxel-based chemotherapy in patients with castration-resistant metastatic prostate cancer
Q88186567A recipe for targeted therapy in prostate cancer
Q45094027Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of (131)I-L19SIP in a prostate cancer patient
Q35999102Acute Respiratory Distress Syndrome after Treatment of Metastatic Prostate Cancer with Taxotere: A Case Report and Literature Review
Q53561315Addressing apoptosis to tumor zip codes.
Q38890711Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
Q38282461Advances in systemic therapies for metastatic castration-resistant prostate cancer
Q44187537Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
Q31152878An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients
Q26799813Androgen deprivation of prostate cancer: Leading to a therapeutic dead end
Q44114886Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Q57139434Angiogenesis inhibitors in the treatment of prostate cancer
Q42332732Another disappointing result, but how good is it?
Q36936900Anti-VEGF agents in metastatic colorectal cancer (mCRC): are they all alike?
Q36330281Anti-VEGF therapies in the clinic
Q26851183Anti-angiogenesis in prostate cancer: knocked down but not out
Q33770680Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Q47147286Antiangiogenic therapies in urogenital malignancies: Fiction or fact?
Q36563542Antiangiogenic therapy for cancer: an update
Q53664329Antiangiogenic therapy--evolving view based on clinical trial results.
Q35966757Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.
Q39000185Antibody therapeutics for treating prostate cancer: where are we now and what comes next?
Q38099046Antimitotic agents for the treatment of patients with metastatic castrate-resistant prostate cancer
Q87115788Association of genetic variants in VEGF-A with clinical recurrence in prostate cancer patients treated with definitive radiotherapy
Q35202464Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
Q87060049Bevacizumab did not reduce the risk of anemia associated with chemotherapy: an up-to-date meta-analysis
Q43497234Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups
Q38237318Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups
Q41612851Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis
Q38024852Bevacizumab treatment of prostate cancer
Q57456564Biomarkers and Bone Imaging Dynamics associated with Clinical outcomes of Oral Cabozantinib Therapy in Metastatic Castrate Resistant Prostate Cancer
Q34695003Biomarkers for anti-angiogenic therapy in cancer.
Q36243296Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer
Q38136271Bone microenvironment-targeted manipulations for the treatment of osteoblastic metastasis in castration-resistant prostate cancer
Q33864723Bone-targeting agents in prostate cancer
Q38066590Brain metastases from prostate cancer: an emerging clinical problem with implications for the future therapeutic scenario.
Q33946929Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial
Q57107233Can RECIST response predict success in phase 3 trials in men with metastatic castration-resistant prostate cancer?
Q38371293Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients
Q39002111Cardiovascular toxicities of systemic treatments of prostate cancer.
Q38076273Castrate-resistant prostate cancer: postdocetaxel management
Q35864027Castration-resistant prostate cancer: mechanisms, targets, and treatment.
Q35865011Castration-resistant prostate cancer: systemic therapy in 2012
Q39511732Castration-resistant prostate cancer: targeted therapies and individualized treatment
Q38121792Cell mates: paracrine and stromal targets for prostate cancer therapy.
Q36181578Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures
Q35776240Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer
Q27008883Chemotherapy and its evolving role in the management of advanced prostate cancer
Q38555599Chemotherapy in Prostate Cancer
Q28078477Chemotherapy options in castration-resistant prostate cancer
Q27334654Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial
Q99629837Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review
Q39247534Combination of vinblastine and oncolytic herpes simplex virus vector expressing IL-12 therapy increases antitumor and antiangiogenic effects in prostate cancer models
Q58579384Combined Performance of Screening and Variable Selection Methods in Ultra-High Dimensional Data in Predicting Time-To-Event Outcomes
Q94528678Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel
Q39427133Comparison of futility monitoring guidelines using completed phase III oncology trials
Q34386577Critical appraisal of cabazitaxel in the management of advanced prostate cancer
Q38030595Current and emerging treatments in the management of castration-resistant prostate cancer
Q36253388Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer
Q38317384Current role of cabozantinib in metastatic castration-resistant prostate cancer
Q37860950Current treatment strategies for castration-resistant prostate cancer
Q51102220Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial.
Q91996335Developing and Validating Risk Assessment Models of Clinical Outcomes in Modern Oncology
Q38208820Development of cabozantinib for the treatment of prostate cancer
Q42183155Doceaqualip in a patient with prostate cancer who had an allergic reaction to conventional docetaxel: A case report
Q28294857Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial
Q41082307Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial
Q35572535Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial
Q41704777Docetaxel for advanced prostate cancer: how early to start?
Q44701341Docetaxel in castration-resistant prostate cancer: a single-centre experience.
Q33416977Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.
Q42125455Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer
Q35298058Docetaxel-based therapy with and without antiangiogenic agents as first-line chemotherapy for castration-resistant prostate cancer: A meta-analysis of nine randomized controlled trials
Q38028012Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer
Q38815759Dose-Dependent Therapeutic Distinction between Active and Passive Targeting Revealed Using Transferrin-Coated PGMA Nanoparticles.
Q50850244Drug development in prostate cancer: time to embrace RECIST?
Q34139362Drug resistance in metastatic castration-resistant prostate cancer
Q30538388Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapy
Q37721529Dynamic contrast-enhanced magnetic resonance imaging in prostate cancer clinical trials: potential roles and possible pitfalls
Q35764986Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis
Q42970939ECF chemotherapy for liver metastases due to castration-resistant prostate cancer
Q57107045Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials
Q26786618Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Q46024539Efficacy of anti-VEGF agents in the treatment of elderly hepatocellular carcinoma: a systematic review.
Q52592629Emerging Therapies in Metastatic Prostate Cancer.
Q38586459Emerging agents for the therapy of advanced prostate cancer
Q38166018Emerging drugs for prostate cancer.
Q37980450Emerging novel therapies for advanced prostate cancer
Q35999255Emerging targeted therapies for castration-resistant prostate cancer
Q37876194Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer
Q34367585End points of clinical trials in metastatic castration-resistant prostate cancer: A systematic review
Q37425136Enhanced diagnostic accuracy for quantitative bone scan using an artificial neural network system: a Japanese multi-center database project
Q36353291Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer
Q27010542Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer
Q26861575Evolving treatment approaches for the management of metastatic castration-resistant prostate cancer - role of radium-223
Q37311904Foxm1 expression in prostate epithelial cells is essential for prostate carcinogenesis.
Q36293995From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer
Q37826274Future directions in castrate-resistant prostate cancer therapy.
Q33621387Glucocorticoids and prostate cancer treatment: friend or foe?
Q26827975Growth factor and signaling pathways and their relevance to prostate cancer therapeutics
Q64124364Identification of a Genomic Region between and Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance)
Q43867243Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment.
Q38959645Immunotherapy for prostate cancer: False promises or true hope?
Q50420907Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer
Q39349569Impact of single-agent daily prednisone on outcomes in men with metastatic castration-resistant prostate cancer
Q38956775Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
Q38480926In vivo passage of human prostate cancer cells in mice results in stable gene expression changes affecting numerous cancer-associated biological processes
Q36729895Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials
Q33904867Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis
Q38261859Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials
Q35745925KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells
Q38050465Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer
Q39204706Lessons learned from adult clinical experience to inform evaluations of VEGF pathway inhibitors in children with cancer.
Q47122203Liver Metastases in Prostate Carcinoma Represent a Relatively Aggressive Subtype Refractory to Hormonal Therapy and Short-Duration Response to Docetaxel Monotherapy
Q34608976Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer
Q37388624Low dose of interferon-α improves the clinical outcomes of docetaxel in patients with castration-resistant prostate cancer: A pilot study
Q40645773Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer: is there a clinical benefit?
Q35575488MET and VEGF: synergistic targets in castration-resistant prostate cancer
Q37354571Management of docetaxel failures in metastatic castrate-resistant prostate cancer
Q26851177Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant
Q35948297Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer
Q38181005Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics
Q26799585Molecular landscape of prostate cancer: implications for current clinical trials
Q30393012Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer
Q37127044Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer
Q35955451Neutralizing S1P inhibits intratumoral hypoxia, induces vascular remodelling and sensitizes to chemotherapy in prostate cancer
Q36866291New and emerging therapies for bone metastases in genitourinary cancers
Q38206684New developments in the treatment of castration resistant prostate cancer
Q42344607New immunotherapeutic paradigms for castration-resistant prostate cancer
Q91045442Non-proteolytic calpain-6 interacts with VEGFA and promotes angiogenesis by increasing VEGF secretion
Q38116358Novel therapeutic approaches for the treatment of castration-resistant prostate cancer
Q34249263Novel therapies for metastatic castrate-resistant prostate cancer
Q36665708Novel therapies for the treatment of advanced prostate cancer
Q37227787On model specification and selection of the Cox proportional hazards model.
Q89682703Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy
Q53266501Optimal management of bone metastases in prostate cancer.
Q90699186Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel
Q44640343Overcoming chemotherapy resistance in prostate cancer
Q36687323P-Rex1 Promotes Resistance to VEGF/VEGFR-Targeted Therapy in Prostate Cancer
Q38246587PSA response rate as a surrogate marker for median overall survival in docetaxel-based first-line treatments for patients with metastatic castration-resistant prostate cancer: an analysis of 22 trials
Q26772883Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science
Q36213475Personalized cancer medicine--advances and socio-economic challenges
Q36871685Perspectives on treatment of metastatic castration-resistant prostate cancer
Q39796533Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Q38267175Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents
Q35328550Phase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer
Q37218730Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial
Q53702293Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer.
Q58596102Phase I/II study evaluating the safety and clinical efficacy of temsirolimus and bevacizumab in patients with chemotherapy refractory metastatic castration-resistant prostate cancer
Q37137426Phase II Study of Pomalidomide in Patients with Castration-Resistant Prostate Cancer
Q36864032Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer
Q56334475Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)
Q33406047Phase II trial of bevacizumab and satraplatin in docetaxel-pretreated metastatic castrate-resistant prostate cancer
Q33429309Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.
Q92451337Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer
Q42927772Phase III trials with docetaxel-based combinations for metastatic castration-resistant prostate cancer: time to learn from past experiences.
Q36056197Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer
Q36975969Potential use of custirsen to treat prostate cancer
Q36668489Power and sample size calculations for SNP association studies with censored time-to-event outcomes
Q37354526Preoperative therapy for localized prostate cancer: a comprehensive overview
Q37325001Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy
Q90344454Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways
Q27011642Quo vadis: advanced prostate cancer-clinical care and clinical research in the era of multiple androgen receptor-directed therapies
Q38977239RAS interaction with PI3K p110α is required for tumor-induced angiogenesis.
Q39257661Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer
Q35660931Recent advances in the therapy of castration-resistant prostate cancer: the price of progress
Q55343985Recent advances on the progressive mechanism and therapy in castration-resistant prostate cancer.
Q38125501Recent advances revolutionize treatment of metastatic prostate cancer
Q27022567Recent progress in pharmaceutical therapies for castration-resistant prostate cancer
Q58729601Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials
Q48272997Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.
Q33949406Risks and benefits with bevacizumab: evidence and clinical implications
Q28075965Role of Chemotherapy and Mechanisms of Resistance to Chemotherapy in Metastatic Castration-Resistant Prostate Cancer
Q41858027SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing
Q38615715Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC).
Q27022715Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy
Q28251240Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer
Q60156253Sipuleucel-T
Q47772214Sipuleucel-T for the treatment of prostate cancer: novel insights and future directions
Q35128716Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments
Q36285594Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer
Q47234339Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: 'plus or minus' may be a minus
Q38974777Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy
Q35555303Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial
Q53772302Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC).
Q26852544Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline
Q38295983Targeted prodrug approaches for hormone refractory prostate cancer.
Q42905122Targeted therapy of urological tumours. Experimental field or established therapeutic approach?
Q92446657Targeting Angiogenesis in Prostate Cancer
Q36931715Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate cancer
Q41143231Targeting MRP4 expression by anti-androgen treatment reverses MRP4-mediated docetaxel resistance in castration-resistant prostate cancer
Q38723404Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?
Q38053680Targeting angiogenesis as a promising modality for the treatment of prostate cancer
Q37993137Targeting angiogenesis for the treatment of prostate cancer
Q38184622Targeting metastatic castration-resistant prostate cancer: mechanisms of progression and novel early therapeutic approaches.
Q88186561Targeting notch in prostate cancer--combination is the key
Q27022821Targeting the adaptive molecular landscape of castration-resistant prostate cancer
Q26770428Tasquinimod in the treatment of castrate-resistant prostate cancer - current status and future prospects
Q38075446Tasquinimod: a novel angiogenesis inhibitor-development in prostate cancer.
Q39231548The Androgen Receptor and VEGF: Mechanisms of Androgen-Regulated Angiogenesis in Prostate Cancer
Q38938475The Role of the Microenvironment in Prostate Cancer-Associated Bone Disease
Q36163344The STAMPEDE trial: paradigm-changing data through innovative trial design
Q35039889The biology of castration-resistant prostate cancer
Q36515526The changing landscape in the treatment of metastatic castration-resistant prostate cancer
Q37913983The changing therapeutic landscape of castration-resistant prostate cancer
Q35059214The course of metastatic prostate cancer under treatment
Q41830553The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer.
Q37227713The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90
Q38769470The evolving role of chemotherapy in prostate cancer
Q38374417The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer
Q90663624The future of clinical trials in urological oncology
Q46720614The hypothalamic-pituitary-gonadal axis and prostate cancer: implications for androgen deprivation therapy
Q26824086The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review
Q28687241The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer
Q42575268The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions
Q38575004The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target
Q38223389The use of luteinizing hormone-releasing hormone analogues is still an indispensable element of therapy in castrate-resistant prostate cancer
Q36326737Therapeutic cancer vaccine fulfills the promise of immunotherapy in prostate cancer
Q38195723Therapeutic options and multifaceted treatment paradigms in metastatic castrate-resistant prostate cancer
Q47121370Toxicity, Adverse Events, and Quality of Life Associated with the Treatment of Metastatic Castration-Resistant Prostate Cancer
Q49578235Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer
Q56932681Trial watch: Monoclonal antibodies in cancer therapy
Q28550733Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy
Q45719740Tumour angiogenesis: an elusive target in castration-resistant prostate cancer
Q38262816Tyrosine kinase inhibitors in the treatment of prostate cancer: taking the next step in clinical development
Q38176143Update in systemic therapy of urologic malignancies.
Q37590738Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.
Q87197964Urological cancer: Is docetaxel the 'black widow' of mCRPC drugs?
Q38086420Validation and clinical utility of prostate cancer biomarkers.
Q38745926Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.
Q91997710Vessel co-option in cancer
Q57133648[Therapy of castration-resistant prostate cancer]

Search more.